Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA Reviewing ILD Risks for Erleada, Xtandi
October 30, 2019
- MHLW Orders Label Revisions for Takecab to Include Pancytopenia to ADR List
October 30, 2019
- CEFP Members Prod Govt to Set Value-Based Target for Generic Promotion, but MHLW Wary
October 29, 2019
- Insurance Coverage of Cancer Genomic Profiling Tests in Early Stage Is Difficult: MHLW Official
October 29, 2019
- 1,419 ADR Victim Relief Claims Recieved in FY2018: MHLW
October 29, 2019
- 1st Topical JAK Inhibitor in Line for Japan Approval in January
October 28, 2019
- Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
October 28, 2019
- Xolair Up for Review for Pollen Allergy, Taltz for Ankylosing Spondylitis on Oct. 31
October 25, 2019
- Kenporen Pushes for No Health Coverage or Higher Copay for OTC-Like Drugs
October 25, 2019
- Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
- Chuikyo Payer Rep Moots Higher Prices for Biosames to Incentivize Biosimilar Development
October 24, 2019
- Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
October 24, 2019
- Discussions on PMD Law Amendment Bill Start in Extraordinary Diet
October 24, 2019
- Pharma Industry Seeks Cooperation from LDP Lawmakers on Pricing Challenges
October 23, 2019
- Industry to Politicians: Start Vaccine Discussions before Approval to Eliminate Lag Time
October 21, 2019
- Chuikyo OKs Insurance Coverage for Chugai’s Companion Diagnostic to Rozlytrek
October 21, 2019
- 1 Case of Person-to-Person Transmission of Xofluza-Resistant Flu Virus Confirmed in Japan
October 17, 2019
- MHLW Taking Public Comments on Rx-to-OTC for Mosapride
October 17, 2019
- 1st Topical JAK Inhibitor Up for MHLW Panel Review Oct. 25, Ono’s Cachexia Drug Still Shelved
October 15, 2019
- MHLW Orphan Status Dropped for Actemra, Rifampicin
October 15, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…